Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/tumor-parameters-clinical-and-pathological-responses-medical-bdvTbpzZ0d
References (11)
-
G. Bonadonna, P. Valagussa, C. Brambilla, L. Ferrari, A. Moliterni, M. Terenziani, M. Zambetti (1998)
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 1
-
S. Amat, P. Bougnoux, Frédérique Penault-Llorca, F. Fétissof, H. Curé, Fabrice Kwiatkowski, J. Achard, G. Body, J. Dauplat, P. Chollet (2003)
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rateBritish Journal of Cancer, 88
-
T. Buchholz, K. Hunt, G. Whitman, A. Sahin, G. Hortobagyi (2003)
Neoadjuvant chemotherapy for breast carcinomaCancer, 98
-
P. Chollet, S. Charrier, E. Brain, H. Curé, I. Praagh, V. Feillel, M. Latour, J. Dauplat, Misset Jl, J. Ferrière (1997)
Clinical and pathological response to primary chemotherapy in operable breast cancer.European journal of cancer, 33 6
-
Etienne Brain, C. Garrino, J. Misset, I. Carbonero, M. Itzhaki, Esteban Cvitkovic, E. Goldschmidt, F. Burki, C. Regensberg, E. Pappo, R. Hagipantelli, M. Musset (1997)
Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.British Journal of Cancer, 75
-
S. Amat, F. Penault-Llorca, H. Curé, Guillaume Bouedëc, J. Achard, I. Praagh, V. Feillel, M. Mouret-Reynier, J. Dauplat, P. Chollet (2002)
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.International journal of oncology, 20 4
-
I. Praagh, H. Curé, B. Leduc, S. Charrier, G. Bouedec, J. Achard, J. Ferrière, V. Feillel, M. Latour, J. Dauplat, P. Chollet (2002)
Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.The oncologist, 7 5
-
T Buchholz (2003)
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risksCancer, 98
-
(1958)
NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION -
J. Pierga, E. Mouret, V. Diéras, V. Laurence, P. Beuzeboc, T. Dorval, T. Palangié, M. Jouve, A. Vincent-Salomon, S. Scholl, J. Extra, B. Asselain, P. Pouillart (2000)
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerBritish Journal of Cancer, 83
-
B. Chevallier, H. Roché, J. Olivier, P. Chollet, P. Hurteloup (1993)
Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response RateAmerican Journal of Clinical Oncology, 16
- Publisher
- Springer Journals
- Copyright
- Copyright © 2005 by Humana Press Inc.
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general; Internal Medicine
- ISSN
- 1357-0560
- eISSN
- 1559-131X
- DOI
- 10.1385/MO:22:3:233
- pmid
- 16110134
- Publisher site
- See Article on Publisher Site
Abstract
The aim of the current study is an analysis of tumor parameters, clinical and pathological responses, medical management, and survival on 710 operable breast cancer patients who received neoadjuvant chemotherapy from 1982 to 2004 and were grouped into four successive periods according to diagnosis date: (1) 1982–1989; (2) 1990–1994; (3) 1995–1999; and (4) 2000–2004.
Journal
Medical Oncology – Springer Journals
Published: Jun 3, 2007